8-K: XOMA Royalty Reports First Quarter 2025 Financial Results, Highlights Pipeline Advancements

XOMA Royalty Corporation reports a net income of $2.4 million for Q1 2025, driven by pipeline advancements and strategic acquisitions.

Summary

• XOMA Royalty Corporation reported its first quarter 2025 financial results on May 13, 2025.
• The company achieved a net income of $2.4 million, a significant improvement from the $8.6 million net loss in the first quarter of 2024.
• Cash receipts for the quarter totaled $18.0 million, including $13.4 million in royalty receipts and $4.6 million from milestones and fees.
• The company acquired an economic interest in Castle Creek Biosciences' D-Fi (FCX-007) through a syndicated royalty financing transaction.
• XOMA Royalty sold all unpartnered Kinnate assets during the quarter.
• R&D expenses increased to $1.3 million due to pass-through licensing fees and clinical trial costs related to KIN-3248.
• G&A expenses decreased slightly to $8.1 million, primarily due to lower stock compensation costs.
• The company repurchased 25,828 shares of its common stock for $0.5 million.
• XOMA Royalty had cash and cash equivalents of $95.0 million as of March 31, 2025.
• The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen's tovorafenib was accepted for review by the European Marketing Authority (EMA).

Sentiment

Score: 8

Explanation: The document presents a positive outlook with improved financial results, strategic acquisitions, and pipeline advancements. The management's comments are optimistic, and the company's future prospects appear promising.

Positives

• The company achieved net income of $2.4 million, a substantial improvement from the previous year's loss.
• Cash receipts were strong at $18.0 million, driven by royalty receipts and milestone payments.
• The acquisition of an economic interest in Castle Creek Biosciences' D-Fi (FCX-007) adds a promising Phase 3 asset to the portfolio.
• The sale of unpartnered Kinnate assets streamlines the portfolio.
• Share repurchases indicate management's confidence in the company's value.
• The company received a $4.0 million milestone related to Day One and Ipsen's MAA filing with the EMA.
• Takeda's Phase 3 trial initiation for mezagitamab triggered a $3.0 million milestone payment, net, to XOMA Royalty.

Negatives

• R&D expenses increased significantly due to pass-through licensing fees and clinical trial costs.
• The company reported other expense, net, of $0.1 million in the first quarter of 2025, compared to other income, net, of $2.0 million in the comparable period of 2024.
• Cash and cash equivalents decreased from $106.4 million at the end of 2024 to $95.0 million as of March 31, 2025.

Risks

• The success of XOMA Royalty is dependent on the success of its partners' drug development programs, which are subject to regulatory and clinical risks.
• The company's future performance is subject to market conditions and interest rate fluctuations.
• The company's forward-looking statements are based on assumptions that may not prove accurate, and actual results could differ materially.

Future Outlook

Management believes a path to sustained cashflow generation is tangible, driven by accelerating royalty receipts and a robust pipeline.

Management Comments

• Owen Hughes, Chief Executive Officer of XOMA Royalty, stated that the first quarter highlights included the progression of key pipeline assets, solid cash receipts, and an increase in share repurchase activity.
• Tom Burns, Chief Financial Officer of XOMA Royalty, commented that the company received $18 million in cash in the first quarter, and that the company's line of sight on becoming cash flow positive on a consistent basis exclusively from the cash payments received from royalties grows clearer.

Industry Context

XOMA Royalty operates in the biotech royalty aggregator space, acquiring future economics associated with therapeutic candidates. This model provides non-dilutive funding to biotech companies, allowing them to advance their drug candidates.

Comparison to Industry Standards

• It is difficult to compare XOMA Royalty directly to other companies due to the unique nature of its royalty aggregation business model.
• However, similar companies in the royalty space include DRI Healthcare Trust and Ligand Pharmaceuticals, which also focus on acquiring royalty streams from pharmaceutical products.
• XOMA Royalty's Q1 2025 revenue growth significantly outpaces the industry average, driven by key milestones and commercial sales.

Stakeholder Impact

• Shareholders benefit from the improved financial performance and share repurchase program.
• Biotech companies receive non-dilutive funding through XOMA Royalty's royalty aggregation model.
• Patients may benefit from the advancement of therapeutic candidates in XOMA Royalty's portfolio.

Next Steps

• The European Medicines Agency (EMA) decision regarding Day One's Marketing Authorization Application (MAA) for tovorafenib is anticipated.
• Rezolute is expected to complete enrollment in the sunRIZE Phase 3 clinical trial, with topline data expected in December 2025.
• Gossamer / Chiesi will present topline results from the Phase 3 PROSERA study.
• Dar Bioscience aims to make Sildenafil Cream available via prescription in the fourth quarter of 2025 and commence Phase 3 clinical trials.

Key Dates

Keywords

royalty, XOMA Royalty Corporation, financial results, milestone, acquisition, pipeline, biotech